HE4 in gynecological cancers: Report of a European investigators and experts meeting

Clinical Chemistry and Laboratory Medicine

Volumn 50, Issue 12, 2012, Pages 2127-2136

  Plebani, Mario ^a,b  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

CA 125; Cancer biomarker; Endometrial cancer; Epithelial ovarian cancer; HE4; Risk of Ovarian Malignancy Algorithm

Indexed keywords

ACID PROTEIN; CA 125 ANTIGEN; HE4 PROTEIN; UNCLASSIFIED DRUG;

ALGORITHM; ANTIGEN DETECTION; ARTICLE; CONSENSUS; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOSIS; ENDOMETRIUM CANCER; EUROPE; GLOMERULUS FILTRATION RATE; GYNECOLOGIC CANCER; HORMONAL THERAPY; HUMAN; KIDNEY FUNCTION; MEDICAL EXPERT; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

ALGORITHMS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MONITORING, PHYSIOLOGIC; PROGNOSIS; PROTEINS;

EID: 84872836890     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0373     Document Type: Article

References (30)

1. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod 1991;45: 350-7.
2. Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999;238:375-85.
3. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65: 2162-9.
4. Galgano MT, Hampton GM, Frierson HF Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006;19:847-53.
5. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker of ovarian carcinoma. Cancer Res 2003;63: 3695-700.
6. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008;108:402-8.
7. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 2008;110:374-82.
8. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100:1315-9.
9. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Analysis 2009;23:331-5.
10. Montagnana M, Lippi G, Danese E, Franchi M, Guidi GC. Usefulness of serum HE4 in endometriotic cysts. Br J Cancer 2009;101:548.
11. Nolen B, Velikokhkatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010;117:440-5.
12. Bordin L, Fiore C, Donà G, Andrisani A, Ambrosini G, Faggian D, et al. Evaluation of erythrocyte band 3 phosphotyrosine level, glutathione content, CA-125, and human epididymal secretory protein E4 as combined parameters in endometriosis. Fertil Steril 2010;94:1616-21.
13. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
14. Moore RG, Jaube-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs. the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010;203:e1-6.
15. Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta 2011;412:1447-53.
16. Bolstad N, Øijordsbakken M, Nustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumor Biol 2012;33:141-8.
17. Sharma R, Hook J, Kumar M, Gabra H. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 2008;44:251-6.
18. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922-9.
19. NICE Clinical Guideline 122. The recognition and initial management of ovarian cancer. 2011. Available at www.nice.org.uk/guidance/CG122.
20. Sturgeon CM, Duffy MJ, Walker G. The National Institute for Health and Clinical Excellence (NICE) guidelines for early detection of ovarian cancer: the pivotal role of the clinical laboratory. Ann Clin Biochem 2011;48:295-9.
21. Ferrazzi E, Lissoni AA, Dordoni D, Trio D, Redaelli L, Rusconi C, et al. Differentiation of small adnexal masses based on morphologic characteristics of transvaginal sonographic imaging: a multicenter study. J Ultrasound Med 2005;24: 1467-73.
22. Kong S-Y, Han MH, Yoo H-J, Hwang JH, Lim MC, Seo SS, et al. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann Surg Oncol 2012;19: 1707-12.
23. Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev 2011;20:2496-506.
24. Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, et al. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer 2011;21:1573-8.
25. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer 2011;104: 1418-25.
26. Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, et al. Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. Clin Chem Lab Med 2012;50:2189-98.
27. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem 2011;57:1534-44.
28. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011;49:521-5.
29. Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA 125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med 2011;49:527-34.
30. Park Y, Kim Y, Lee EY, Lee J-H, Kim H-S. Reference ranges for HE4 and CA 125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer 2012;130:1136-44.